Paper Title

ANTICANCER AGENTS

Article Identifiers

Registration ID: IJNRD_211014

Published ID: IJNRD2312266

DOI: Click Here to Get

Authors

Manisha Govind Bhatane , Manjusha S Sanap , Tejal Santosh Bagwe , Dr. Nitin Mohire

Keywords

Cancer , uncontrolled cell division, Oncology, Anti-cancer drug, Cytotoxic action, Chemotherapy, surgery , radiation therapy

Abstract

Cancer is a frightfull disease and represents one of the biggest healthcare issue for human race and demands a proactive strategy for cure . Cancer is a condition marked by irregular and unregulated cellular proliferation . Oncology is a branch of a science that deal with the tumors and cancer

How To Cite (APA)

Manisha Govind Bhatane , Manjusha S Sanap, Tejal Santosh Bagwe, & Dr. Nitin Mohire (December-2023). ANTICANCER AGENTS. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(12), c606-c632. https://ijnrd.org/papers/IJNRD2312266.pdf

Issue

Volume 8 Issue 12, December-2023

Pages : c606-c632

Other Publication Details

Paper Reg. ID: IJNRD_211014

Published Paper Id: IJNRD2312266

Downloads: 000121981

Research Area: Pharmacy

Country: mumbai, maharashtra, India

Published Paper PDF: https://ijnrd.org/papers/IJNRD2312266.pdf

Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2312266

About Publisher

Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)

ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG

Publication Timeline

Peer Review
Through Scholar9.com Platform

Article Preview: View Full Paper

Call For Paper

Call For Paper - Volume 10 | Issue 10 | October 2025

IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.

The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.

Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.

How to submit the paper?

Important Dates for Current issue

Paper Submission Open For: October 2025

Current Issue: Volume 10 | Issue 10 | October 2025

Impact Factor: 8.76

Last Date for Paper Submission: Till 31-Oct-2025

Notification of Review Result: Within 1-2 Days after Submitting paper.

Publication of Paper: Within 01-02 Days after Submititng documents.

Frequency: Monthly (12 issue Annually).

Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.

Subject Category: Research Area

Call for Paper: More Details